Zileuton

111406-87-2

C11H12N2O2S

DMSO : >= 100 mg/mL (423.21 mM)

Metabolic Enzyme/Protease

Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties. In Vitro: In anti-CD3-treated cells, IL-2 decreases in zileuton-treated and untreated cells with increasing incubation time. Zileuton likely reduces IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer^[2]. In Vivo: In zileuton (5 mg/kg, p.o.) treated I/R rat, the effect of zileuton to decrease NF-kappaB expression does not change significantly in the presence of COX inhibitors, and the group reveals significantly lower level of NF-kappaB staining. Zileuton (5 mg/kg, p.o.) treatment given to I/R rats decreases apoptotic index significantly. Zileuton has no significant effect on increased serum TNF-alpha levels in I/R group^[1]. Zileuton (1, 200 mg/kg) inhibits the polyp formation in APC^delta468 colon and small intestine. Zileuton treatment inhibits the proliferation rates of non epithelial cells in polyps, and increases the apoptosis rates in polyps in rat. There is significant increase in the number of apoptotic cells in the Zileuton-treated cells both in small intestine and in the colon. The reduced proliferation rate may significantly contribute to the reduction of polyposis in both the small intestine and colon of Zileuton-fed APC^delta468 mice^[3].